New Delhi: India’s indigenous COVID-19 vaccine, Covaxin, was found to have an efficacy rate of 77.8 per cent against symptomatic COVID-19, according to a long-awaited analysis published in The Lancet.
Covaxin is developed by the India government’s medical research agency and Hyderabad-based Bharat Biotech International Ltd.
Covaxin, which uses traditional, inactivated-virus technology, “induces a robust antibody response” two weeks after two doses are given, the medical journal was quoted as saying in a statement by Bloomberg.
The trial involving 24,419 participants aged 18-97 years between November 2020 and May 2021 in India found no vaccine-related deaths or adverse events, the journal said.
Funded by Bharat Biotech and the Indian Council of Medical Research (ICMR) and partially authored by officials at both bodies, the interim study was in line with the company’s earlier efficacy and safety announcements.
ALSO READ: UK Approves Covaxin; No Quarantine For Fully Vaccinated Travellers
New Delhi: India will again ask Canada for the extradition of designated Khalistani terrorist Arshdeep Singh…
Berhampur: Police have arrested a man from West Bengal for allegedly claiming himself to be…
Mumbai: Carving a niche for himself in Bollywood was not a cakewalk for ‘The Family…
Mumbai: Mukesh Khanna’s Indian superhero series ‘Shaktimaan’ has been making headlines for quite some time…
Bhubaneswar: As part of Odisha government's tiger relocation project, second tigress from Maharashtra arrived at…
New Delhi: Hours after Delhi’s Environment Minister Gopal Rai said that the third phase of…
Mumbai: ‘Pushpa’ actor Allu Arjun is currently busy promoting his highly-anticipated film ‘Pushpa: The Rule’,…
Cuttack: The Mahanadi river banks in Odisha's Cuttack city are all decked up for inauguration…